先声药业（02096）：SIM0500获里程碑，年内有望PoC

Investment Rating - The investment rating for the company is maintained as "Buy" with a target price of HKD 19.82 [1][5][11] Core Insights - The company has received a milestone payment of USD 40 million from AbbVie for SIM0500, indicating positive progress in clinical development [1][2] - SIM0500 is expected to read out Phase I clinical data within the year, with the drug showing superior anti-tumor activity in preclinical studies compared to other competitors [2][3] - The company is advancing its product pipeline globally, with several products expected to achieve proof of concept (PoC) and initial clinical data this year [4] Financial Projections - The company’s revenue is projected to reach RMB 7.646 billion in 2025, with a compound annual growth rate (CAGR) of 14% from 2025 to 2027 [5][11] - Adjusted net profit forecasts for 2025, 2026, and 2027 are RMB 11.8 billion, RMB 14.0 billion, and RMB 15.2 billion respectively [5][11] - The earnings per share (EPS) estimates are RMB 0.45, RMB 0.54, and RMB 0.59 for 2025, 2026, and 2027 respectively [5][11] Product Development and Pipeline - SIM0500 is a tri-antibody TCE that has received FDA Fast Track Designation and is currently in Phase I clinical trials in both China and the US [2][3] - The company is also advancing other products such as SIM0613 and SIM0505, with the latter expected to read out initial data this year [4] - The ADC platform and other innovative therapies are positioned to enhance the company's global competitiveness [4]